Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Bintie Biotechnology logo — Advancing biomedical innovation with groundbreaking immune c...

Bintie Biotechnology

Advancing biomedical innovation with groundbreaking immune cell therapies for targeting solid tumors.

Founded 2021 Series A Total: $100.00M Biotechnology

General Information

Company Name Bintie Biotechnology
Founded Year 2021
Industries Biotechnology
Funding Stage Series A
Social

Get notified when Bintie Biotechnology moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Bintie Biotechnology

Bintie Biotechnology is a pioneering biomedical technology enterprise founded in 2021 that focuses on advancing biomedical innovation with groundbreaking immune cell therapies for targeting solid tumors. With its primary products being novel immune cell formulations, the company operates within the Biotechnology industry.

The latest milestone for Bintie Biotechnology was a CNY100.00M Series A investment at 31 October 2023, which was backed by notable investors including SDIC Ventures, Winguide Huangpu Pharmaceutical, and Yuanxi Haihe Fund.

This recent investment signifies a vote of confidence from the venture capital community and highlights the potential seen in Bintie Biotechnology's innovative approach to immune cell therapies for solid tumors.

Taxonomy: biomedical innovation, immune cell therapy, solid tumors, clinical stage, biotechnology enterprise, novel immune cell formulations

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 3
Investor Investor
•••• •••• 		31 Oct 2023

Bintie Biotechnology Alternatives & Competitors

Bintie Biotechnology vs
revimmune
revimmune

Comprehensive T-cell support and advanced immune therapies for treating complex immune disorders.

5 employees
Manufacturing
Bintie Biotechnology vs
SQZ Biotechnologies
SQZ Biotechnologies United States

Unlocking the full potential of cell therapies for patients around the world

Grant
18 employees
Biotechnology, Health and Wellness
Bintie Biotechnology vs
Quell Therapeutics
Quell Therapeutics United Kingdom

Transformational Therapies, Transforming Lives

Series B
149 employees

FAQ About Bintie Biotechnology

Advancing biomedical innovation with groundbreaking immune cell therapies for targeting solid tumors.
Bintie Biotechnology was founded in 2021.
Bintie Biotechnology operates in the following industries: Biotechnology.
Bintie Biotechnology has completed 1 funding round, raising a total of $100.00M. The latest funding stage is Series A.
Top alternatives and competitors to Bintie Biotechnology include revimmune , SQZ Biotechnologies, Quell Therapeutics, Cogen Therapeutics, Talaris Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bintie Biotechnology and revimmune are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Bintie Biotechnology and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes